Literature DB >> 32828702

PRDM12: New Opportunity in Pain Research.

Sophie Imhof1, Tomislav Kokotović2, Vanja Nagy3.   

Abstract

PRDM12 is a newly identified causative gene for a type of congenital insensitivity to pain disorder, which is characterized by the inability to perceive pain. Here, we discuss the (patho)physiology of PRDM12 function and the opportunities and challenges those data provide for novel therapeutic approaches in various pain disorders.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Mendelian disorders; PRDM12; congenital insensitivity to pain; nociception

Mesh：

Substances：

Year:  2020        PMID： 32828702     DOI： 10.1016/j.molmed.2020.07.007

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  4 in total

1.  Loss of Prdm12 during development, but not in mature nociceptors, causes defects in pain sensation.

Authors:  Mark A Landy; Megan Goyal; Katherine M Casey; Chen Liu; Helen C Lai
Journal:  Cell Rep       Date:  2021-03-30       Impact factor: 9.423

Review 2.  PRDM12 in Health and Diseases.

Authors:  Monica Rienzo; Erika Di Zazzo; Amelia Casamassimi; Patrizia Gazzerro; Giovanni Perini; Maurizio Bifulco; Ciro Abbondanza
Journal:  Int J Mol Sci       Date:  2021-11-06       Impact factor: 5.923

3.  Transcription factor mesenchyme homeobox protein 2 (MEOX2) modulates nociceptor function.

Authors:  Tomislav Kokotović; Ewelina M Lenartowicz; Michiel Langeslag; Cosmin I Ciotu; Christopher W Fell; Angelica Scaramuzza; Michael J M Fischer; Michaela Kress; Josef M Penninger; Vanja Nagy
Journal:  FEBS J       Date:  2022-02-16       Impact factor: 5.622

4.  Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry.

Authors:  Sandra Sanchez-Roige; Pierre Fontanillas; Mariela V Jennings; Sevim B Bianchi; Yuye Huang; Alexander S Hatoum; Julia Sealock; Lea K Davis; Sarah L Elson; Abraham A Palmer
Journal:  Mol Psychiatry       Date:  2021-11-02       Impact factor: 13.437
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.